Human T-cell lymphotropic viruses type I (HTLV-I) and type II (HTLV-II) are two closely related retroviral pathogens of emerging significance among intravenous drug users (IDU). The rate of infection is 20% in this at risk population with seroprevalence ranging widely from region to region, 0.4 - 20 %, in the United States. The majority of IDU are infected with HTLV-II (84%) and the remaining infected with HTLV-I. Unfortunately, the infection rate is likely to increase in IDU as documented rather dramatically in a number of studies from Spain and Sweden. The project is to continue the detailed analysis of the humoral immune response to HTLV-1 and HTLV-II among IDU. To date, we succeeded in producing an extensive panel of human monoclonal antibodies (HMAbs) to virtually all HTLV structural proteins from peripheral B-cells of an infected IDU and other individuals. The molecular and biochemical characterizations of viral epitopes identified by these HMAbs have led to the development of better diagnostic tools for HTLV-I and -II disease association studies which has contributed to the recognition of HTLV-II associated neurological disorders. The functional characterization of these antibodies has identified HTLV conformational epitopes mediating virus neutralization. With these tools in hand and mounting evidence of HTLV-II neurological disease association that are already well-established with HTLV-I, we will explore the involvement of viral proteins in spontaneous T-cell activation observed in some infected individuals and their immune response to these proteins during the disease course as possible risk factors for HTLV neuropathy. The contribution of co-infection with HIV will be assessed since many IDU are infected with both viruses. Our premise is that virus encoded proteins expressed on the surface of infected cells are potential mediators of HTLV-induced T-cell activation and proliferation. Through these studies and the continuation of our effort to define the protective immune response to HTLV, we will gain further insights in HTLV pathogenesis and ultimately, in the design of anti-HTLV-I and -II therapies as well as potential vaccines.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA006596-11
Application #
6174629
Study Section
Special Emphasis Panel (ZDA1-KXA-N (26))
Program Officer
Coulis, Paul A
Project Start
1990-05-01
Project End
2003-03-31
Budget Start
2000-04-01
Budget End
2001-03-31
Support Year
11
Fiscal Year
2000
Total Cost
$440,930
Indirect Cost
Name
Stanford University
Department
Pathology
Type
Schools of Medicine
DUNS #
800771545
City
Stanford
State
CA
Country
United States
Zip Code
94305
Op De Beeck, Anne; Voisset, Cecile; Bartosch, Birke et al. (2004) Characterization of functional hepatitis C virus envelope glycoproteins. J Virol 78:2994-3002
Cocquerel, Laurence; Quinn, Elizabeth R; Flint, Mike et al. (2003) Recognition of native hepatitis C virus E1E2 heterodimers by a human monoclonal antibody. J Virol 77:1604-9
Lozach, Pierre-Yves; Lortat-Jacob, Hugues; de Lacroix de Lavalette, Agnes et al. (2003) DC-SIGN and L-SIGN are high affinity binding receptors for hepatitis C virus glycoprotein E2. J Biol Chem 278:20358-66
Triyatni, Miriam; Vergalla, John; Davis, Anthony R et al. (2002) Structural features of envelope proteins on hepatitis C virus-like particles as determined by anti-envelope monoclonal antibodies and CD81 binding. Virology 298:124-32
Hadlock, Kenneth G; Yang, Qing; Rowe, Judy et al. (2002) Epitope mapping of human monoclonal antibodies recognizing conformational epitopes within HTLV type 1 gp46, employing HTLV type 1/2 envelope chimeras. AIDS Res Hum Retroviruses 18:57-70
Chan, C H; Hadlock, K G; Foung, S K et al. (2001) V(H)1-69 gene is preferentially used by hepatitis C virus-associated B cell lymphomas and by normal B cells responding to the E2 viral antigen. Blood 97:1023-6
Hadlock, K G; Gish, R; Rowe, J et al. (2001) Cross-reactivity and clinical impact of the antibody response to hepatitis C virus second envelope glycoprotein (E2). J Med Virol 65:23-9
Quinn, E R; Chan, C H; Hadlock, K G et al. (2001) The B-cell receptor of a hepatitis C virus (HCV)-associated non-Hodgkin lymphoma binds the viral E2 envelope protein, implicating HCV in lymphomagenesis. Blood 98:3745-9
Hadlock, K G; Lanford, R E; Perkins, S et al. (2000) Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes. J Virol 74:10407-16
Soares, L R; Tsavaler, L; Rivas, A et al. (1998) V7 (CD101) ligation inhibits TCR/CD3-induced IL-2 production by blocking Ca2+ flux and nuclear factor of activated T cell nuclear translocation. J Immunol 161:209-17

Showing the most recent 10 out of 25 publications